Treatment of acute migraine by a partial rebreathing device: A randomized controlled pilot study.

Cephalalgia · 2018 · PMC6158684 · PMID 30134739

Europe PMC DOI

hedged sentence

0.0960

closest p · 1.9× alpha

0.0960

boldest claim

The sentences

did not reach statistical significancep = 0.096so close (0.05 < p ≤ 0.1)

The primary end point (headache intensity difference between first aura symptoms and two hours after treatment (0–3 scale) – active/sham difference) did not reach statistical significance (−0.55 (95% CI: −1.13–0.04), p = 0.096), whereas the difference in percentage of attacks with pain relief at two hours was significant ( p = 0.043), as was user satisfaction ( p = 0.022).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.